ECZTRA Archives - Medical Conferences

AD patients with stable response fare well with a monthly dose of tralokinumab

Presented By

Prof. Stephan Weidinger, University of Kiel, Germany

Trial

ECZTRA1 and 2

Conference

EADV 2021

Type

Peer-reviewed article

18 November 2021 13:25

Efficacious 2-year AD control with IL-13 inhibitor tralokinumab

Presented By

Prof. Andrew Blauvelt, Oregon Medical Research Center, USA

Trial

ECZTEND

Conference

EADV 2021

Type

Peer-reviewed article

18 November 2021 13:22

Meaningful sleep improvement with IL-13 inhibition

Presented By

Prof. Jonathan Silverberg, George Washington University, USA

Trial

Phase 3, ECZTRA

Conference

EADV 2020

Type

Peer-reviewed article

17 December 2020 14:33

Effects IL-13 blocker improves with longer treatment duration

Presented By

Prof. Eric Simpson, Oregon Health & Science University, USA

Trial

Phase 3, ECZTRA

Conference

EADV 2020

Type

Peer-reviewed article

17 December 2020 12:37

IL-13 blocker tralokinumab effective in AD

Presented By

Prof. Eric Simpson

Trial

ECZTRA

Conference

AAD 2020

Type

Peer-reviewed article

6 August 2020 07:06